No abstract

No abstract

No abstract

There is still debate over the use of drains following hip fracture surgery. We have performed a systematic review and meta-analysis of the literature for randomised trials that related to the use of closed suction drains following hip fracture surgery. Six studies involving 664 patients were identified.

Aging produces several changes in body composition. Aging is associated with an increase in body fat and changes in their distribution pattern. The risks associated with an increase in body fat or from low weight are different in the elderly. As a result, the World Health Organization recommends a modification in the Body Mass Index (BMI) in the elderly. The BMI cutoffs currently used to assess the nutritional status of the elderly are: underweight (BMI <22kg/m2), normal weight (BMI between 22 and 27kg/ m2) and overweight (BMI> 27kg/m2). The prevalence of many complications associated with obesity-such as hypertension, diabetes mellitus, cardiovascular disease, some cancers, sleep apnea/hypopnea syndrome and osteoarthritis-also increases during the aging process. However, several studies have shown that overweight in elderly patients is not associated with increased mortality. Studies show that overweight reduces all-cause mortality among the elderly. This reduction is a paradox that contradicts evidences for other age groups. It should be noted, however, that sarcopenia associated with lower weight accounts for this increase in mortality. In obese patients a worrying picture is, therefore, the development of sarcopenic obesity. We thus conclude that weight control in the elderly has many peculiarities. Overweight is beneficial for the elderly, hence the adjustment in BMI values. Recognizing and managing comorbid conditions directly related to weight excess, at the same time, avoiding involuntary weight changes should be a priority in the care of the elderly.

Context and Objective Hypertriglyceridemia is implicated in ~5% of cases of acute pancreatitis. It is assumed that intravenous insulin is effective in lowering triglyceride (TG) concentrations in hypertriglyceridemia-associated acute pancreatitis (HAAP). However, the efficacy of intravenous insulin versus conservative management alone is not known. Design and Setting Charts of 106 patients who were admitted with HAAP and had TG concentrations &gt;1000 mg/dL at admission were reviewed. Patients who received intravenous insulin for at least 8 hours were included in the intravenous insulin group, while the rest were considered to have received conservative management. We compared the change in TG concentrations from baseline in the 2 groups. Results Fifty-one patients received intravenous insulin while 55 patients were managed conservatively. Baseline TG concentrations were higher in the intravenous insulin group (median [25th, 75th percentile] 3307 [2106, 4425] mg/dL vs 2304 [1416, 2720] mg/dL; P &lt; 0.001). The TG concentrations declined rapidly in both groups, reaching below 1000 mg/dL by day 3 and &lt; 500 mg/dL by day 4. TG concentrations in the intravenous insulin group had decreased by 69% and 85% on days 2 and 4, respectively. The fall in the conservative management group was 63% and 79%, which was not statistically different than the change in the intravenous insulin group. Conclusion Our results show that intravenous insulin did not result in a more rapid fall in TG compared with conservative treatment in patients with HAAP. Fasting and intravenous fluids were effective in lowering TG concentrations rapidly, with no further contribution from insulin.

Context Cardiovascular outcome trials (CVOT) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrated reduction of major adverse cardiovascular events (MACE), cardiovascular deaths (CVD), and renal outcomes. Objective Assist in the prescribing decision regarding severity of illness and risk for adverse events. Design Meta-analysis of the major CVOT and previous meta-analyses. Main Outcome Measures Six trials of GLP-1 RA (51 762 subjects) and 4 trials of SGLT2i (33 457 subjects) showed both drug classes reduced MACE and CVD versus controls, with neither class preferred (comparison GLP1-RA vs SGLT2i: relative rate [rr] MACE 1.09, 95% confidence interval [CI] 0.97, 1.22, P = ns; rr CVD 1.04, 95% CI 0.87, 1.24, P = ns). Hospitalization for heart failure (HHF) improved with SGLT2i (rr 0.68, CI 0.61, 0.76, P &lt; 0.001) but not with GLP-1 RA, (rr 0.93, CI 0.86,1.03, P = ns). Meta-regression suggested benefits of the SGLT2i on CVD and HHF were accentuated with the underlying rate of MACE in the cohort (i.e., &gt;10 events/1000pt*year). GLP-1 RA and SGLT2i showed reduction in renal outcomes (GLP-1 RA rr 0.83, CI 0.75, 0.91, p ≤ 0.001, SGLT2i rr 0.67, CI 0.57, 0.79, P &lt; 0.001) without a preferential difference (GLP-1 RA vs SGLT2i, rr 1.24, CI 0.95, 1.61, P = ns; relative difference (rd) 0.005, CI -0.011, 0.021, P = ns). Serious adverse events for SGLT2i were mycotic genital infections in women (number needed to harm [NNH] = 13 and diabetic ketoacidosis NNH = 595. Gastrointestinal intolerance was the serious adverse event in the GLP1-RA class (NNH = 35). Conclusion GLP-1 RA and SGLT2i classes showed similar reduction in MACE, CVD, and renal outcomes. SGLT2i have advantages over GLP-1 RA in reduction in HHF.

No abstract